Success Metrics

Clinical Success Rate
100.0%

Based on 16 completed trials

Completion Rate
100%(16/16)
Active Trials
0(0%)
Results Posted
31%(5 trials)

Phase Distribution

Ph phase_4
5
31%
Ph phase_1
1
6%
Ph phase_2
10
63%

Phase Distribution

1

Early Stage

10

Mid Stage

5

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
1(6.3%)
Phase 2Efficacy & side effects
10(62.5%)
Phase 4Post-market surveillance
5(31.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

16 of 16 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(16)

Detailed Status

Completed16

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (6.3%)
Phase 210 (62.5%)
Phase 45 (31.3%)

Trials by Status

completed16100%

Recent Activity

0 active trials
Showing 5 of 16
completedphase_1

Ribavirin 200 mg Tablets Under Fasting Conditions

NCT00835146
completedphase_4

PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

NCT00087633
completedphase_4

A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response

NCT01033448
completedphase_2

Study of SCY-635, Pegasys and Copegus in Hepatitis C

NCT01265511
completedphase_2

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.

NCT00517439
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT00835146Phase 1

Ribavirin 200 mg Tablets Under Fasting Conditions

Completed
NCT00087633Phase 4

PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

Completed
NCT01033448Phase 4

A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response

Completed
NCT01265511Phase 2

Study of SCY-635, Pegasys and Copegus in Hepatitis C

Completed
NCT00517439Phase 2

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.

Completed
NCT00377182Phase 2

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.

Completed
NCT01331850Phase 2

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

Completed
NCT00963885Phase 2

A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Completed
NCT01220947Phase 2

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

Completed
NCT00869661Phase 2

A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

Completed
NCT01482403Phase 2

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Completed
NCT00412334Phase 4

SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.

Completed
NCT00077636Phase 4

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

Completed
NCT01271790Phase 2

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Completed
NCT01225380Phase 2

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Completed
NCT00275548Phase 4

Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16